Sagiru Hamza Abdullahi

In-silico activity prediction, structure-based drug design, molecular docking and pharmacokinetic studies of selected quinazoline derivatives for their antiproliferative activity against triple negative breast cancer (MDA-MB231) cell line

Sagiru Hamza Abdullahi, Adamu Uzairu, Gideon Adamu Shallangwa et al. · Bulletin of the National Research Centre/Bulletin of the National Research Center · 2022 · 56 citations · Full text

Breast Oncology, Bioorganic Chemistry, Drug Target +23

Molecular docking studies of some benzoxazole and benzothiazole derivatives as VEGFR-2 target inhibitors: In silico design, MD simulation, pharmacokinetics and DFT studies

Sagiru Hamza Abdullahi, Abu Tayab Moin, Adamu Uzairu et al. · Intelligent Pharmacy · 2023 · 44 citations · Full text

Chemo-informatics activity prediction, ligand based drug design, Molecular docking and pharmacokinetics studies of some series of 4, 6-diaryl-2-pyrimidinamine derivatives as anti-cancer agents

Sagiru Hamza Abdullahi, Adamu Uzairu, Muhammad Tukur Ibrahim et al. · Bulletin of the National Research Centre/Bulletin of the National Research Center · 2021 · 37 citations · Full text

Drug Target, Pharmacotherapy, Pre-clinical Pharmacology +20

Computational modeling, ligand-based drug design, drug-likeness and ADMET properties studies of series of chromen-2-ones analogues as anti-cancer agents

Sagiru Hamza Abdullahi, Adamu Uzairu, Gideon Adamu Shallangwa et al. · Bulletin of the National Research Centre/Bulletin of the National Research Center · 2022 · 34 citations · Full text

Molecular Docking , ADMET and Pharmacokinetic properties predictions of some di-aryl Pyridinamine derivatives as Estrogen Receptor (Er+) Kinase Inhibitors

Sagiru Hamza Abdullahi, Adamu Uzairu, Gideon Adamu Shallangwa et al. · Egyptian Journal of Basic and Applied Sciences · 2022 · 25 citations · Full text

Estrogen Receptor, Kinase Inhibitors, Pharmacotherapy +18